Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
NASDAQ:VBIV|TSX:VBV 1
VBIVaccines,Inc.222ThirdStreet,Suite2241
Cambridge,MA02142(617)830-3031
NASDAQ : VB I V T SX : VBV
IMMUNO -ONCOLOGY SUMMIT AUGUST 3 0 2 0 1 7
HARNESSINGTHE IMMUNOGENICITY OF FOREIGNVIRAL CMVANTIGENSTO
TARGETSOLIDTUMORS
NASDAQ:VBIV|TSX:VBV 2
Certainstatementsinthispresenta-oncontainforward-lookingstatementswithinthemeaningofthePrivateSecuri-esLi-ga-onReformActof1995orforward-lookinginforma-onunderapplicableCanadiansecuri-eslegisla-on(collec-vely,“forward-lookingstatements”)thatmaynotbebasedonhistoricalfact,butinsteadrelatetofutureevents,including,withoutlimita-on,statementscontainingthewords“believe”,“may”,“plan”,“will”,“es-mate”,“con-nue”,“an-cipate”,“intend”,“expect”,“goals”andsimilarexpressions.Allstatementsotherthanstatementsofhistoricalfactincludedinthispresenta-onareforward-lookingstatements.Suchforward-lookingstatementsarebasedonanumberofassump-ons,including,withoutlimita-on,assump-onsregardingthesuccessfuldevelopmentand/orcommercializa-onofthecompany’sproducts,suchasthereceiptofnecessaryregulatoryapprovals;generaleconomiccondi-ons;thatthecompany’sbusinessisabletooperateasan-cipatedwithoutinterrup-ons;compe--vecondi-ons;andchangesinapplicablelaws,rulesandregula-ons.Althoughmanagementbelievesthattheassump-onsmadeandexpecta-onsrepresentedbysuchstatementsarereasonable,therecanbenoassurancethataforward-lookingstatementcontainedhereinwillprovetobeaccurate.Actualresultsanddevelopmentsmaydiffermateriallyfromthoseexpressedorimpliedbytheforward-lookingstatementscontainedherein,and,evenifsuchactualresultsanddevelopmentsarerealizedorsubstan-allyrealized,therecanbenoassurancethattheywillhavetheexpectedconsequencesoreffects.Factorswhichcouldcauseactualresultstodiffermateriallyfromcurrentexpecta-onsinclude,withoutlimita-on:thefailuretosuccessfullydeveloporcommercializethecompany’sproducts;adversechangesingeneraleconomiccondi-onsorapplicablelaws,rulesandregula-ons;andotherfactorsdetailedfrom-meto-meinthecompany’sreportsfiledwiththeU.SSecuri-esandExchangeCommissionandtheCanadianSecuri-esCommissions.Giventheserisks,uncertain-esandfactors,youarecau-onednottoplaceunduerelianceonsuchforward-lookingstatementsandinforma-on,whicharequalifiedintheiren-retybythiscau-onarystatementandaremadeonlyasofthedateofthispresenta-on.Allforward-lookingstatementsandinforma-onmadehereinarebasedonthecompany’scurrentexpecta-ons,andthecompanyundertakesnoobliga-ontoreviseorupdatesuchforward-lookingstatementsandinforma-ontoreflectsubsequenteventsorcircumstances,exceptasrequiredbylaw.
CauHonaryStatementRegardingForward-LookingInformaHon
NASDAQ:VBIV|TSX:VBV 3
Agenda1
2
3
4
Intro&eVLPPlaWormOverview
SignificanceofCMVasaTumorTarget
VBI-1901IND-EnablingData
Summary
NASDAQ:VBIV|TSX:VBV 4
ConvergenceofVaccinology&Immuno-oncology–CancerVaccines3.0
XCancerTestesAnHgens
PepHde&AdjuvantTechnologies
AutologousDCVaccines
CheckpointBlockade
NeoAnHgens
?CAR-Ts
LiveViralVaccines
‘ReducHonist’PepHdeSubunitvaccines
RecProtein+/-Adjuvants
VLPs
? ?
mRNA&DNA
ThemesofConvergence:• AnGgenselecGon
• Immunogenicity• SelfvsForeign
• AnGgendelivery• Recogni-onof
Threat
• Safety• Risk-benefit
• Personalizedvs.universal
ViralVector
?
X
NASDAQ:VBIV|TSX:VBV 5NASDAQ:VBIV|TSX:VBV
eVLPPlaWorm:envelopedvirus-likeparHclesthatleverageinnateimmunesignalingtosHmulateanH-tumorimmunity
eVLPOverview
Customizable constructs that mimicenvelopedvirusesastheyoccurinnature:• K e y s t r u c t u r a l c o m p o n e n t srepresented
• AnGgensinnaturalconformaGon• NoreplicaGonmachinery• NaturallyprocessedbydendriGccells
ü NaGvely sGmulate adapGve and innateimmunity
ü Promote uptake by anGgen-presenGngcells
ü InternalanGgencapacityforCD8targetsü Surface anGgen capacity for CD4 and Bcell(anGbody)responses
ü Scalable and easy to manufacture @GMP
ü SafeinclinicLipidBilayer
MLVGagcreatesVirus-LikeStructure
CD8T-CellAnHgen
TargetSurfaceAnHgen
Poten-alforaddi-onalsurfaceimmunotherapytargets
eVLPFeatures
eVLPOp5mizedforSurfaceAn5gen
eVLPOp5mizedforInternalAn5gen
NASDAQ:VBIV|TSX:VBV 6
Target RaHonale
VBI-1901:TherapeuHcCMVforSolidTumors
SchemaHc
AnHbodyTargets gB
T-cellTargets gB(CD4+),pp65(CD8+)
TargetIndicaHonTreatmentofCMV+
glioblastoma,breastcancer,otherCMV+solidtumors
RaHonaleTargetsbothhumoral&cellularimmunitytopromotebroadimmunity&tumorclearance
VBI-1901:RaHonallydesignedtherapeuHcCMVvaccineforsolidtumors
CMV-gB
• ViralfusionproteinforAPCuptake
• Majoran-body&CD4T-cellepitopes
• S-mulatesinnateimmunity
CMV-pp65• PrimaryCD8T-celltarget• FulllengthovercomesHLArestric-on
‘Foreign’TumorAssociatedViralAn-gens(TAVA)arenaturallyimmunogenic
Virus-likeStructureS-mulatesInnateImmunity&PromotesUptakebyAn-genPresen-ngCells(APCs)
NASDAQ:VBIV|TSX:VBV 7
SignificanceofCMVasaTumorTarget
NASDAQ:VBIV|TSX:VBV 8
Note:ImagederivedfromNatureReviewAr-cleon“NeoAn-gens”:Schumacher&Schrieber,Science,April2015
ForeignviralanHgens,likeCMV,enableimmunetargeHngin“cold”tumorswherecheckpointsinhibitorshavebeenlesssuccessful
FrequentNeoan5genForma5onTypically“HoFer”Tumors
OccasionalNeoan5genForma5onTypically“Colder”Tumors
Checkpointsuccessdependentonmuta-onfrequency,neoan-gens
Opportunitytotargetforeignviraltumoran5gensinCMV+tumortypes
• ForeignviraltumoranGgensarehighlyimmunogenicandinherently‘hot’• VBI-1901candrivepotentresponsesagainstCMV+tumorswhereneo-anGgensand‘self’
tumor-associatedanGgenshaveweakerimmunogenicity
NASDAQ:VBIV|TSX:VBV 9
GBM
BroadevidencesupportsCMVasacancerimmunotherapeuHctarget
BodyofEvidenceSuggestsaCMVVaccineThatCanS5mulateDCs&Res5mulateCMV-SpecificT-cellsHasPoten5alforClinicalEfficacy
• PrinsRM(2008)–Autologous,GBMtumorlysateDCvaccineo Singleimzn.increasedCMVpp65-specificCD8+Tcellsfrom0.2%to4.4%
• CroughT(2012)–SinglepaGentreceiving4infusionsofautologousCMV-specificT-cellso MRIrevealedimprovementwithstablediseasereportedfor17months
• SchuesslerA(2014)–10paGentsreceiving3-4infusionsofautologousCMV-specificT-cellso 10recurrentGBMpts,3-4infusionsofautologousCMV-specificTcellso AchievedmedianOSof403daysandonlyminoradverseevents
• MitchellDA(2015)–CMV-specificDCvaccinewithtetanuspre-condiGoningo OS(>36.6months)vs.controlcohortwithmedianOSof18.5monthso SurvivalwascorrelatedwithincreasedlevelsofCCL3
• BaGchK(2017)–CMV-specificDCvaccinewithGM-CSF&Temozolomideo OSincreased(>41.1months)vshistoriccontrolo SurvivalcorrelatedtoCMV-pp65-specificINF-gammaT-cells
OtherCMV+TumorsBroadSupportforHighCMVExpression,Poten5alfor
VBI-1901ClinicalEfficacy
• Wolmer-SolbergN(2013)IntJCancer,133,2351-61Neuroblastoma
Medulloblastoma
Breast
Colorectal
• BaryawnoN(2011)JClinInvest121,4043-4055;• LibardS(2014)PLoSONE9,e108861
• TaherC(2013)JClinVirol54,240;• HarkinsLE(2010)Herpesviridae1,8
• Wolmer-Solberg,InternaGonalCMVConference–April2017
NASDAQ:VBIV|TSX:VBV 10
Duke-ledstudydemonstratesthatCMVdendriHccellvaccinescanincreasepp65immunity(BaHchetal,2017)
• >3Gmeslongerprogression-freesurvival• >2Gmeslongeroverallsurvival• pp65cellularresponseincreased
• 11paGentsreceivedatleast3dosesofpp65-dentriGccellsaierdose-intensifiedtemozolomide
TrialDesign ClinicalResults
RelevanceforVBI-1901:ü BuildsonbodyofevidencedemonstraGngCMV-immunityimpactssurvivalü pp65DCvaccineanalogoustoeVLP(whicharereadilytakenupbyDCsinvivo)ü VBI-1901offerspotenGaltobuildonoutcomewith“Off-the-shelf”vaccine
Pre-vaccine Post3rdDose
pp65LoadedDendriHcCells+GM-CSF(ThreeDoses)
NASDAQ:VBIV|TSX:VBV 11
VBI-1901IND-EnablingData
NASDAQ:VBIV|TSX:VBV 12
VBI-1901:ElicitsBalancedCellular&HumoralImmunityTumorClearancebyCTLsisKnowntobeEnhancedbyCD4&AnHbodyResponses
Naïvemice(n=4or8/group)wereimmunizedsubcutaneouslyat0and4weeks,andsplenocytesharvested10dayslater.SplenocytesfromtheabovegroupsweresGmulatedwithrecombinantCMVgBorpp65anGgens;responsesagainstemptyeVLPsweresubtractedfromallresponses.TheendpointGter(EPT)isbasedonthehighestdiluGonofserareacGvewithrecombinantgBproteininELISAwithanO.D.of0.1orgreater.
pp65-specific Th1 cells
VBI-1901
GM-CSF
0
1
2
3
CD
3+ CD
4+ IFNγ+
(%)
gB-specific CTLs
VBI-1901
GM-CSF
0.0
0.2
0.4
0.6
0.8
1.0
CD
3+ CD
8+ per
forin
+ (%
) gB-specific antibody response
VBI-190
1
GM-CSF
100
101
102
103
104
105
An
tibo
dy
Tite
r (G
MT
)
NASDAQ:VBIV|TSX:VBV 13
• ImmatureDCsgeneratedbycultureofMUTZ-3myeloidcelllinefor6daysinGM-CSF• DCsexposedtoeVLPsorcontrolrecombinantprotein(humanserumalbumin)for48hours• InducGonofproinflammatoryIL-8cytokineandCCL3chemokinedeterminedbyCBAassaywithcomparableresultsinrepeat
independentassays(n=3)
VBI-1901:PotenHal“Off-the-Shelf”DendriHcCellVaccine
VBI-1901Recruits(CCL3)andAcHvates(IL-8)DendriHcCells
CCL3
0 50 100 150 2000
20
40
60
80
Sec
retio
n (p
g/m
l)
Dose (µg)
CCL3: gB/pp65 eVLPsCCL3: Human serum albumin
IL-8
0 20 40 60 80 1000
500
1000
1500
2000
2500
Dose (µg)
Sec
retio
n (p
g/m
l)
gB/pp65 eVLPsHuman serum albumin
NASDAQ:VBIV|TSX:VBV 14
VBI-1901:SHmulatesInnateImmunity
IL-8-Monocytes
12.37
24.73 37
.149
.460
20000
40000
60000
80000
100000GaggB/pp65
TP (µg/mL)
IL-8
(pg/
mL)
IL-6-Monocytes
12.37
24.73 37
.149
.460
2000
4000
6000
8000
10000GaggB/pp65
TP (µg/mL)
IL-6
(pg/
mL)
IL-1b-Monocytes
12.37
24.73 37
.149
.460
1000
2000
3000
4000
5000
gB/pp65Gag
TP (µg/mL)
IL-1β
(pg/
mL)
TNF-Monocytes
12.37
24.73 37
.149
.460
50
100
150GaggB/pp65
TP (µg/mL)
TNF
(pg/
mL)
eVLPparHclessHmulateIL-8(independentofanHgen)InclusionofgB/pp65anHgenssHmulatesaddiHonalpro-inflammatorycytokines
Note:HumanmonocyteswerepurifiedbynegaGveselecGonto>90%purityandsGmulatedwithincreasingconcentraGonsofeVLPs.CytokinesweremeasuredbyCBA.
NASDAQ:VBIV|TSX:VBV 15
gBMonoclonalCanNeutralizeSHmulaHonofInnateCytokineProfile
71%ê
82%ê83%ê
46%ê
VBI-1901:SHmulatesInnateImmunityAnHgenspecificupregulaHonofpro-inflammatorycytokinesisdrivenbyCMV-gB
NASDAQ:VBIV|TSX:VBV 16
VBI-1901:Re-sHmulatesCMV-specificImmunityinHumanExVivoSamples
ResHmulaHonofCD4+&CD8+T-cellsinExVivoHumanSamples
CD4+IFN-γ+
VBI-190
1
Recom
binan
t gB+pp
650.0
0.2
0.4
0.6
0.8
1.0
Freq
uenc
y of
Res
pons
e (%
) CD8+IFN-γ+
VBI-190
1
Recom
binan
t gB+pp
650.0
0.5
1.0
1.5
2.0
2.5
CMV+ H
ealth
yGBM
Medull
oblas
toma
Breast
101
102
103
104
105
CC
L3 S
ecre
tion
(pg/
ml)
SHmulaHonofCCL3inCMV+Tumors–Correlatedto>O.S.byMitchelletal(2015)
• VBI-1901sGmulateskeybiomarkersofeffecGveCMV-specificanG-tumorimmunity• DeliveryofCMVpp65&gBineVLPenhancespotencyrelaGvetorecombinantprotein
NASDAQ:VBIV|TSX:VBV 17
VBI-1901:BoostsCMVpp65-specificIFN-γTcellResponsesinMacaques
VBI:CMV+Rhesusmacaque-matchedCMVpp65ELISPOTSbeforeandaier2vaccinaGonswithVBI-1901+GM-CSF.ELISPOTtestedforIFN-γusingoverlappingpp65pepGdepools.
BaHchetal(2017)ObservedCD8T-cellImmunityaqer3-doses&ImprovedOverallSurvivalVBI-1901ResHmulatesCD8ImmunityinCMV+Monkeys–BasisforClinicalEvaluaHon
VBI-1901+GM-CSF
Week 0 Week 60
50
100
150
200
250IF
N-γ
-sec
retin
g T
cells
(spo
ts/1
06 ce
lls)
Pre-vaccine Post2ndDose
VBI-1901+GM-CSF(TwoDoses)
NASDAQ:VBIV|TSX:VBV 18
ClarificaGon(DepthfiltraGon)
ConcentrateparGcles(TangenGalflowfiltraGon)
InacGvateresidualhostDNAandadvenGciousvirus
(Benzonase/βPLTx&diafiltraGon)
WashandConcentrate(DiafiltraGon&ultracentrifugaGon)
Sterilize(filter)
VBI-1901:OverviewofCMCProcessProcessopHmizedtopreserveparHcleintegrity&meetFDAstandards
AssayDescripHon TestResult
ResidualhostcellDNA(quanGtaGvePCR)
1.4ng/µgpp65
Residualhostcellprotein(ELISA)
4ng/µgpp65
ParGclecount(nsEM) 5.3x1010/ml
NASDAQ:VBIV|TSX:VBV 19
VBI-1901:INDEnablingTox&Safety
Prescan 5min 0.5hr 1hr 2hr
3hr 4hr 8hr 24hr 48hr
72hr 96hr 120hr 144hr 168hr
192hr 216hr 240hr 336hr
In Vivo Imaging ID injection of AF700-eVLP Dorsal
Peak fluorescence from whole body imaging appears to be at 1hr.
Site of injection
Brain
Prescan 5min 0.5hr 1hr 2hr
3hr 4hr 8hr 24hr 48hr
72hr 96hr 120hr 144hr 168hr
192hr 216hr 240hr 336hr
In Vivo Imaging ID injection of AF700-eVLP Dorsal
Peak fluorescence from whole body imaging appears to be at 1hr.
Site of injection
Brain Prescan 5min 0.5hr 1hr 2hr
3hr 4hr 8hr 24hr 48hr
72hr 96hr 120hr 144hr 168hr
192hr 216hr 240hr 336hr
In Vivo Imaging ID injection of AF700-eVLP Dorsal
Peak fluorescence from whole body imaging appears to be at 1hr.
Site of injection
Brain Prescan 5min 0.5hr 1hr 2hr
3hr 4hr 8hr 24hr 48hr
72hr 96hr 120hr 144hr 168hr
192hr 216hr 240hr 336hr
In Vivo Imaging ID injection of AF700-eVLP Dorsal
Peak fluorescence from whole body imaging appears to be at 1hr.
Site of injection
Brain Prescan 5min 0.5hr 1hr 2hr
3hr 4hr 8hr 24hr 48hr
72hr 96hr 120hr 144hr 168hr
192hr 216hr 240hr 336hr
In Vivo Imaging ID injection of AF700-eVLP Dorsal
Peak fluorescence from whole body imaging appears to be at 1hr.
Site of injection
Brain
Control m2-336hr
m3-336hr m4-336hr
Brain
Heart
Lungs
Liver
Kidneys
Spleen Pancreas
Brain
Heart
Lungs
Liver
Kidneys
Spleen Pancreas
Site of injection
Brain
Heart
Lungs
Liver
Kidneys
Spleen Pancreas
Site of injection
Brain
Heart
Lungs
Liver
Kidneys
Spleen Pancreas
Site of injection
Ex Vivo Imaging at 336hr ID injection of AF700-eVLP Organs
Only site of injection had a measurable signal at 336hr.
Control m2-336hr
m3-336hr m4-336hr
Brain
Heart
Lungs
Liver
Kidneys
Spleen Pancreas
Brain
Heart
Lungs
Liver
Kidneys
Spleen Pancreas
Site of injection
Brain
Heart
Lungs
Liver
Kidneys
Spleen Pancreas
Site of injection
Brain
Heart
Lungs
Liver
Kidneys
Spleen Pancreas
Site of injection
Ex Vivo Imaging at 336hr ID injection of AF700-eVLP Organs
Only site of injection had a measurable signal at 336hr.
• StandardToxicologyü NoadverseeventsseenwithVBI-1901ü eVLPsalreadysafelyevaluatedinPhI
• BiodistribuGonStudy
ü VaccineobservedatinjecGonsiteforupto14days(depoteffect)
ü NoaccumulaGoninmajororgans
• Off-targetToxicology
ü AvailableliteraturesaGsfiedFDAthatoff-targetCMVtoxicitywasunlikely(givenpredominanceofCMVintumorvshealthyGssueandhistoryofclinicalsafety)
NASDAQ:VBIV|TSX:VBV 20
VBI’sprophylacHcCMVvaccine(similardesignto1901)achieveddose-dependentimmuneresponsesagainstCMV(interimPh1data)
A[[email protected],100%ofsubjectsseroconvert-Excep5onallyimmunogenicvaccineplaborm
• Seroconversion*in100%ofsubjects
• eVLPshighlyimmunogenicplaxorm:2.0ugdoseis10-50Xlowerthanrecentlyapproved&late-stageVLPproducts
• Adjuvant(alum)enhancesimmunogenicity
*Seroconversiondefinedas4x-foldabovebaseline-ter(industryconven-on)
NASDAQ:VBIV|TSX:VBV 21
Opportunity&ClinicalDevelopmentPlan
NASDAQ:VBIV|TSX:VBV 22
IniHalClinicalDevelopmentofVBI-1901WillFocusonGBM–AProfoundUnmetMedicalNeed
ü GBMisthemostaggressiveformofbraincancer
ü NostandardofcareopGonsaieriniGalsurgery/radiaGon/chemotherapy
ü Invasiveprimarytumormarginsandsecondarytumorsareinterspersedamong
healthyglialGssueandcannotbesafelyoperatedon
ü EsGmatedincidencevariesbycountry
ü US:3.2/100,0001
ü France:4.96/100,0002
ü UK:3.43/100,0003
ü 42.4%survive6months
ü ~90%ofpaGentswillexperiencerecurrentGBM4
1. Ostrumetal,CBTRUSStaGsGcalReport:PrimaryBrainandOtherCentralNervousSystemTumorsDiagnosedintheUnitedStatesin2009–2013–Availableat:h{ps://doi.org/10.1093/neuonc/now207
2. Baldi(2010):h{p://www.ncbi.nlm.nih.gov/pubmed/208697333. www.ncin.org.uk/view?rid=26624. GBIResearch:GlioblastomaMulGformeTherapeuGcsinMajorDevelopedMarketsto2020
NASDAQ:VBIV|TSX:VBV 23
Company/Inst. Approach KeyFinding Take-Away
NovarGs–CTL019 EGFRvIIIspecificCAR-T
EGFRvIIICAR-TcantraffictobrainandexertanG-tumoreffect,tumorselectedtoescape
TargeGngmulGpleepitopes&proteinsmayberequired
BMS–Checkmate143Merck–Keynote028
PD1,PDL1
Opdivo-alonenotsufficient.Keytrudatrialongoing
Fewneo-anGgenstypicalofGBMmaylimitefficacy
Duke– BaGch(etal)pp65loadedautologousDCs
Improvedoverallsurvivalto41monthswithhigh-doseTMZ
MulG-epitopeapproachcanleadtoimprovedsurvival
VBIVaccines
Off-the-shelfgB&pp65eVLPthattargetsDCs
ClinicalStudyThesis:MulGplefulllengthproteinscoveringthemajorCD8,CD4andADCCepitopes,presentedbyviruslikeparGclewillsGmulatebroadimmunitywithanoff-the-shelfapproach
VBI-1901ComparisontoRecentClinicalIOAdvancesinGBM
BreadthofReacHvitymaybeanImportantParameterforEfficacy
NASDAQ:VBIV|TSX:VBV 24
VBI-1901:PotenHal‘Off-the-Shelf’VaccineforCMV+SolidTumors
Off-The-ShelfDesign
BroadPotenHalinCMV+Tumors
StrongPreclinicalDataPackage
ClinicalRaHonale
Milestones
• LeveragesinherentimmunogenicityofCMVtotargetCMV-posiGvetumors
• Easilymanufacturedandscalable
• CMVisexpressedinover90%ofGlioblastoma(GBM),Breast,Colorectal&othersolidtumors
• Highunmetneedin~18,000recurrentGBMpaGents
• ResGmulaGonofCD4andCD8T-cellresponsesinCMV+humansubjectsexvivo&inCMV+RhesusMacaques
• Demonstratedsafetyandtolerability,readyfortheclinic
• ExisGngCMV-targeGngdendriGccellvaccineshaveachieveda>2Xincreaseinoverallsurvivalinglioblastoma
• VBI’sprophylacGcCMVvaccine(alsousingeVLPs)waswell-toleratedandimmunogenicaierjusttwoofthreescheduleddoses(interimPh1data)
• VBIVaccineshasanacceptedINDforVBI-1901• ClinicalstudiesinrecurrentGBMareexpectedtobeginH22017
NASDAQ:VBIV|TSX:VBV 25
VBIVaccines,Inc.222ThirdStreet,Suite2241
Cambridge,MA02142(617)830-3031